US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.